Acceleron Buoyed By Sotatercept’s Promise In PAH
Pipeline Turnaround After 2019 Disappointments
Top-line Phase II results from the PULSAR study suggest Acceleron’s sotatercept is effective as add-on treatment for patients with PAH, and could be a new class of therapy for a still difficult-to-control condition.
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: There was no big M&A, but biopharma CEOs discussed deals they're pursuing. Also, Novartis's Zolgensma reimbursement insights, Sarepta's third DMD filing, Bristol's post-merger progress and more highlights.